1. Dual SGLT1/SGLT2 Inhibition in T1D

2. Unmet Needs in T1D

3. Intestinal SGLT1-Mediated Glucose Absorption

4. Glucose Absorption and Reabsorption in Patients With Diabetes Treated With a Selective SGLT2 Inhibitor

5. Glucose Absorption/Reabsorption in Patients Treated With Dual SGLT1/SGLT2 Inhibitor, Which Inhibits SGLT1 Locally in the GI Tract and SGLT2 Systemically in the Kidney

6. Sotagliflozin inTandem Clinical Program

7. inTandem1, inTandem2, inTandem3 Endpoint Comparisons

8. Sotagliflozin inTandem1/inTandem2 Study Design

9. Sotagliflozin inTandem1/inTandem2 Pooled Baseline Characteristics

10. Sotagliflozin inTandem1/inTandem2 Pooled Analysis HbA1c Levels at Screening and Baseline Week 52

11. Sotagliflozin inTandem1/inTandem2 Pooled Analysis HbA1c Change From Baseline Weeks 24 and 52

12. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Absolute Body Weight (kg) Placebo-Corrected Change From Baseline Weeks 24 and 52

13. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Composite Endpoints at Week 52

14. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Percentage Change in Total Daily, Daily Basal, and Daily Bolus Insulin at Week 52

15. Sotagliflozin inTandem1/inTandem2 Pooled Analysis Proportion of Insulin Reduction Attributable to Basal and Bolus Insulin at Week 52

16. Sotagliflozin inTandem1/inTandem2 CGM Substudy Trial Design

17. Sotagliflozin inTandem1/inTandem2 CGM Substudy Pooled Analysis Time Spent in Glycemic Ranges

18. Sotagliflozin inTandem1/inTandem2 CGM Substudy Pooled Data, 2-Hour PPG

19. Sotagliflozin inTandem3 In Combination With Any Background Insulin

20. Sotagliflozin inTandem3 Net Clinical Benefit

21. Sotagliflozin inTandem3 HbA1c Change From Baseline to Week 24

22. Sotagliflozin inTandem3 More Patients Achieved HbA1c < 7% and Related Benefit-Risk Endpoints vs Insulin Alone

23. Sotagliflozin inTandem1/inTandem2 Pooled Analysis of AEs at Week 52

24. Comparison of Rates of DKA in DEPICT-1 and inTandem3 Trials

25. Sotagliflozin Phase 3 Studies Documented Hypoglycemia (Blood Glucose ≤ 55 mg/dL) Less Frequent With Sotagliflozin

26. Summary of Sotagliflozin inTandem Clinical Program as Adjunct Therapy in Adults With T1D

27. Summary of Sotagliflozin inTandem Clinical Program as Adjunct Therapy in Adults With T1D (cont)

28. Differences in Data for Inhibiting Both SGLT1 and SGLT2 Compared With SGLT2 Alone

29. What Should We Do in Clinic Next Week?

30. Abbreviations

31. Abbreviations (cont)